Literature DB >> 11084109

Rate smoothing with cardiac pacing for preventing torsade de pointes.

S Viskin1, M Glikson, R Fish, A Glick, Y Copperman, L A Saxon.   

Abstract

Cardiac pacing remains one of the most effective means for preventing torsade de pointes in patients with long QT syndrome (LQTS). However, fatal arrhythmias may occur despite combined therapy with beta blockers and pacing, and it is possible that failure of cardiac pacing for preventing arrhythmias in the long run is related (at least in part) to suboptimal pacemaker programming. Preventing sudden pauses may be especially important for preventing arrhythmias in the LQTS because such pauses are highly proarrhythmic in this patient population. Unfortunately, properly functioning pacemakers cannot be expected to prevent postextrasystolic pauses. The use of a pause-prevention pacing algorithm-rate smoothing-for preventing pause-dependent torsade de pointes is described in 12 patients with cardiac arrest or syncope due to congenital LQTS who were followed for 21 +/- 11 months.

Entities:  

Mesh:

Year:  2000        PMID: 11084109     DOI: 10.1016/s0002-9149(00)01228-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  6 in total

1.  Congenital long QT syndrome: diagnosis and management in pediatric patients.

Authors:  Yaniv Bar-Cohen; Michael J Silka
Journal:  Curr Treat Options Cardiovasc Med       Date:  2006-09

2.  Intermittent inhibition of biventricular pacing in a cardiac resynchronization therapy defibrillator.

Authors:  Andrew E Darby; Kenneth C Bilchick
Journal:  Heart Rhythm       Date:  2010-07-21       Impact factor: 6.343

Review 3.  Brugada and long QT-3 syndromes: two phenotypes of the sodium channel disease.

Authors:  Ijaz A Khan; Chandra K Nair
Journal:  Ann Noninvasive Electrocardiol       Date:  2004-07       Impact factor: 1.468

Review 4.  Pharmacological approach to the treatment of long and short QT syndromes.

Authors:  Chinmay Patel; Charles Antzelevitch
Journal:  Pharmacol Ther       Date:  2008-04       Impact factor: 12.310

Review 5.  [Electrical heart diseases--therapy during childhood and adolescence].

Authors:  K Brockmeier; M Emmel; F Pillekamp; N Sreeram
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2005-12

6.  Blinded In Silico Drug Trial Reveals the Minimum Set of Ion Channels for Torsades de Pointes Risk Assessment.

Authors:  Xin Zhou; Yusheng Qu; Elisa Passini; Alfonso Bueno-Orovio; Yang Liu; Hugo M Vargas; Blanca Rodriguez
Journal:  Front Pharmacol       Date:  2020-01-30       Impact factor: 5.810

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.